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Abstract
Background: In oldest-old patients (>80), few trials showed efficacy of treating hypertension and they included
mostly the healthiest elderly. The resulting lack of knowledge has led to inconsistent guidelines, mainly based on
systolic blood pressure (SBP), cardiovascular disease (CVD) but not on frailty despite the high prevalence in oldest-
old. This may lead to variation how General Practitioners (GPs) treat hypertension. Our aim was to investigate
treatment variation of GPs in oldest-olds across countries and to identify the role of frailty in that decision.
Methods: Using a survey, we compared treatment decisions in cases of oldest-old varying in SBP, CVD, and frailty.
GPs were asked if they would start antihypertensive treatment in each case. In 2016, we invited GPs in Europe,
Brazil, Israel, and New Zealand. We compared the percentage of cases that would be treated per countries. A
logistic mixed-effects model was used to derive odds ratio (OR) for frailty with 95% confidence intervals (CI),
adjusted for SBP, CVD, and GP characteristics (sex, location and prevalence of oldest-old per GP office, and years of
experience). The mixed-effects model was used to account for the multiple assessments per GP.
Results: The 29 countries yielded 2543 participating GPs: 52% were female, 51% located in a city, 71% reported a
high prevalence of oldest-old in their offices, 38% and had >20 years of experience. Across countries, considerable
variation was found in the decision to start antihypertensive treatment in the oldest-old ranging from 34 to 88%. In
24/29 (83%) countries, frailty was associated with GPs’ decision not to start treatment even after adjustment for SBP,
CVD, and GP characteristics (OR 0.53, 95%CI 0.48–0.59; ORs per country 0.11–1.78).
Conclusions: Across countries, we found considerable variation in starting antihypertensive medication in oldest-
old. The frail oldest-old had an odds ratio of 0.53 of receiving antihypertensive treatment. Future hypertension trials
should also include frail patients to acquire evidence on the efficacy of antihypertensive treatment in oldest-old
patients with frailty, with the aim to get evidence-based data for clinical decision-making.
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Background
Hypertension is the most important preventable cause of
poor cardiovascular outcome and is responsible for dis-
ability and deaths from stroke, myocardial infarction and
other diseases [1]. Treating hypertension is beneficial
and (since the 1990s) it is known that treatment also re-
duces stroke rates and myocardial infarction in patients
aged >60 years [2–4]. As life expectancy has increased
worldwide, a new term was needed to describe those in
the fastest-growing age group expected to triple within
the next 35 years [5], i.e. the group ‘oldest-old’ is now
defined as those aged >80 years.
The population of the oldest-old is heterogeneous.
Some oldest-old are very healthy whereas others are
multimorbid with complex problems. Although the
group of multimorbid oldest-old is rapidly increasing,
most trials still exclude them. Messerli et al. highlighted
this commonly-applied exclusion by applying exclusion
criteria taken from 13 hypertension trials with oldest-old
participants, to a primary care cohort of hypertensive
patients aged >60 years [6]: in this case, ≥70% of the
oldest-old would have been excluded and they were both
older and sicker.
The exclusion of such a large percentage of oldest-old
has caused a serious gap in our knowledge and in guide-
lines to treat hypertension in patients with multimorbid-
ity. Even more scarce are recommendations for frail
patients: for example, of six current hypertension guide-
lines, only those of the European Society of Hyperten-
sion and of the European Society of Cardiology have a
specific recommendation to leave decisions on antihy-
pertensive therapy in the frail and oldest-old patients to
the treating physician (class I C recommendation) [7].
Due to the current lack of clear evidence, the best
management of hypertension in the oldest-old re-
mains unknown; this may, in turn, lead to clinical
variation. Although it is difficult to quantify, variation
exists in the way that the best available evidence is
applied in clinical practice [8]. Among the diverse
reasons for this variation, the appropriateness of
guidelines for physicians in treating specific groups of
patients is of particular importance. However, to re-
duce clinical variation and improve quality of care/pa-
tient safety, there is a need to assess clinical variation
among the oldest-old patients, who are consistently
excluded from trials but suffer from both multimor-
bidity and frailty.
Therefore, the present study investigates clinical vari-
ation across countries of general practitioners’ (GPs) de-
cisions to start antihypertensive treatment in patients
aged >80 years. Our hypothesis was that frailty would be
an important factor in deciding not to start antihyper-
tensive treatment in clinical practice, although this is not
specifically addressed in most guidelines.
Methods
Design
GPs from different countries were invited to participate
in a survey based on case vignettes.
Setting
The aim was to recruit national representatives (defined
as a GP in contact with a national GP network) of 40
countries on the European continent, and in Brazil and
New Zealand. We also re-contacted six national repre-
sentatives of GP networks participating in a previous
survey [9]. Also invited to participate were: 1) national
representatives of WONCA Europe (European Branch of
the World Organization of National Colleges, Academies
and Academic Associations of General Practitioners/Family
Physicians) [10]; 2) the European General Practice Research
Network (EGPRN) [11]; and 3) the Network of Junior GPs
in Europe (the Vasco da Gama Movement, VdGM) [12].
The study was conducted in accordance with the Dec-
laration of Helsinki [13]. Because the responses of GPs
were collected anonymously, most countries required no
approval from an ethics committee. In countries where
approval was mandatory (Switzerland, Brazil), a waiver
from the ethics committee was obtained. In New Zealand,
approval for the study was granted by the University of
Aukland Ethics Committee.
Participants
All national representatives were asked to include as
many GPs as possible from their GP network. Because
primary care surveys usually score low on response
rates, we regularly reported the numbers of participating
GPs to the national coordinators, so they could send re-
minders if needed. The only inclusion criterium for the
survey was to be actively working as a GP; this was
asked at the beginning of the survey. Participants who
did not meet this criterium (e.g. due to retirement) were
excluded from completing the survey.
Procedures
Beforehand, we developed/tested the survey for optimal
technicality between SurveyMonkey (www.surveymonkey.
com, Palo Alto, CA, USA) and Stata, among five GPs.
Then, to test for clarity/feasibility, the survey was piloted
among a sample of 16 physicians working in Switzerland.
National representatives translated the survey from
English to their own language. Finally, the survey was
available in 21 languages. National representatives of
Greece, Israel and Finland decided to distribute the sur-
vey in English. The correctness of all translations was
evaluated by the team of collaborators.
The survey can be accessed online (see Additional file 1).
First, we asked the GP’s gender, office location (city, subur-
ban, rural), and years of experience working as a GP (in 5-
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years bands). Second, GPs were asked to estimate the
proportions of patients aged >80 years attending their GP
office. Third, eight case vignettes were presented of oldest-
old patients of both gender, presenting for a routine visit in
a GP office without blood pressure-related symptoms and
not receiving any antihypertensive treatment. For each case
vignette, GPs were asked to decide if they would start anti-
hypertensive treatment. All case vignettes differed in three
primary characteristics: systolic blood pressure (SBP), car-
diovascular disease (CVD), and frailty (see Additional file
2). SBP was either 140 mmHg or 160 mmHg. CVD was ei-
ther present (e.g. case vignettes with a history of myocar-
dial infarction or stroke) or absent. Because the condition
of frailty lacks a common definition [14], we stated that
frailty is defined as patients with at least two of the follow-
ing criteria: unintentional weight loss, exhaustion, low level
of activity, muscle weakness, and slow gait speed. Thus, a
patient with a low level of activity and unintentional weight
loss was considered to be frail. To facilitate filling in the
survey, for each case vignette we indicated one of the fol-
lowing statements: “You consider this patient to be frail” or
“You don’t consider this patient to be frail”.
The survey was distributed by email between March 9
and July 31 2016. As the only exception, Ukraine distrib-
uted the survey on paper during a regional GP meeting
because there is insufficient internet access for GPs in
Ukraine.
Statistical analysis
To describe baseline characteristics, proportions were cal-
culated for dichotomized or categorized data, and means
were calculated for continuous data.
To assess international variation in decisions for treat-
ment, per country the crude proportions and confidence
intervals (CI) were calculated for GPs who would start
treatment.
To assess the role of frailty in the decision to start treat-
ment per country, odds ratios (ORs) and CI were calcu-
lated per country using a mixed-effects model adjusted for
GP’s gender, years of experience, office location, preva-
lence of oldest-old in the GP practice, guideline compli-
ance, SBP, and CVD. The mixed-effects model was used
to account for the multiple assessments per GP. The esti-
mate of each country was presented on a forest plot.
For each case vignette, we calculated the crude pro-
portions of GPs starting treatment and also compared
two corresponding case vignettes (e.g. in Case 1 the pa-
tient is not frail, whereas in Case 2 the patient is frail).
To assess the overall influence of SBP, CVD and frailty,
the same mixed-effects model was used but, in addition,
clustering within countries was taken into account.
A two-sided p-value of 0.05 was considered statistically
significant. Analyses were performed with STATA 14.2
(StataCorp, College Station, TX, USA).
Results
From March through July 2016, we contacted 40 na-
tional representatives from Europe, Brazil, Israel, Russia,
and New Zealand and received replies from 29 coun-
tries. Overall, 13,671 GPs were invited, of whom 2585
responded. Subsequently, 42 respondents were excluded
because they were no longer working as a GP, resulting
in 2543 participants. The median response rate was 26%
(IQR 10–62%) (see Additional file 3).
Table 1 presents the baseline characteristics of the par-
ticipating GPs; 52.3% were female, 50.8% lived in a city,
and 37.6% had >20 years of experience. The majority of
GPs (61.3%) estimated the prevalence of the oldest-old
patients in their practice to be >10%.
Overall, the crude proportions of treatment varied
considerably between countries (Fig. 1). For example,
the lowest proportion of treatment was found in the
Netherlands (34.2%; 95% CI 32.0–36.5%) whereas Ukraine
had the highest proportion (88.3%; 95% CI 85.3–90.9%).
Figure 2 shows the GPs’ treatment probability in frail
oldest-old compared to non-frail oldest-old for each of
the 29 countries. Overall, the treatment probability for
all countries was OR 0.59 (95% CI 0.47–0.75) and the
probability per country ranged from OR 0.11 in New
Zealand to 1.78 in the Czech Republic. In 8/29 (28%)
countries (i.e. New Zealand, Finland, Denmark, the
Netherlands, Ireland, Switzerland, France and Israel) we
are 95% confident that GPs would be less likely to
start antihypertensive treatment in the frail oldest-old
patients compared to the non-frail oldest-old patients.
In 16/29 (55%) countries, an OR <1 was found but a
Table 1 Baseline characteristics of participating GPs from 29
countries
Baseline characteristics (N = 2543) n (%)
Female GP 1341 (52.3)
Practice location
City 1292 (50.8)
Suburban 599 (23.6)
Rural 651 (25.6)
Experience as GP
< 5 years 471 (18.5)
5–10 years 445 (17.5)
11–15 years 341 (13.4)
16–20 years 328 (12.9)
> 20 years 956 (37.6)
Self-estimated prevalence of patients >80 years at own practice
< 10% 851 (38.7)
10–20% 865 (39.4)
21–30% 323 (14.7)
> 30% 159 (7.2)
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95% CI including 1; this larger 95% CI was due to
the lower number of respondents per country (<30
per country in 45% of all countries). In 5/29 (17%)
countries, the OR was >1 but (to a large extent) the
95% CI included 1.
GPs’ decision to treat hypertension in the oldest-old
varied considerably, ranging from 17.3% to 96.8% ac-
cording to the specific case vignette (Table 2). The low-
est level of treatment decision was scored in those case
vignettes that included no frailty, no CVD, and a SBP
Fig. 1 National percentages in which general practitioners decide to start antihypertensive treatment in all eight cases of oldest-old patients (unadjusted)
Fig. 2 Influence of frailty on 2053 general practitioners (GPs) when deciding to start antihypertensive treatment per country (adjusteda). aAdjusted
for GP characteristics (gender, experience, location, prevalence of oldest-old, guideline compliance) and patient characteristics (cardiovascular disease,
systolic blood pressure). A mixed-effects model was used to account for multiple assessments per GP. Although 2543 GPs participated, missing data
on GPs’ decisions to treat the eight cases means that only 2053 GPs are included here
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140 mmHg (17.3%; 95% CI 15.7–19.0%). The case vi-
gnettes that included CVD, SBP 160 mmHg and no
frailty scored the highest (96.8%; 95% CI 95.9–97.5%).
Besides frailty (adjusted OR 0.53; 95% CI 0.48–0.59), a
SBP of 140 mmHg (adjusted OR 0.01; 95% CI 0.01–0.01)
and no CVD (adjusted OR 0.29; 95% CI 0.26–0.32) were
also independent factors that caused GPs not to start
treatment.
Discussion
After sampling >2500 GPs in 29 countries, this study re-
vealed large clinical variation in starting antihypertensive
treatment (ranging from 34 to 88%) based on case vi-
gnettes of oldest-old patients. As hypothesized, frailty
proved to be an important patient characteristic for GPs
in deciding whether or not to start antihypertensive
treatment in 24/29 (83%) countries. The probability of a
GP treating a frail patient was almost half that compared
with a GP managing a non-frail patient. Current guide-
lines are clearer about the level of SBP related to initiat-
ing treatment; this was confirmed in the present study
in which GPs were less inclined to start treatment in the
case of SBP 140 mmHg compared to SBP 160 mmHg.
Nevertheless, how to manage frailty will become increas-
ingly important for an increasingly older and multimor-
bid population. When specific data from future trials
that include frail patients become available, hypertension
and other guidelines can be updated accordingly.
Scientific and clinical context of the results
Treatment goals for hypertension are constantly chan-
ging [15]. Recent trials including oldest-old patients indi-
cate aiming at the lower levels of SBP [3, 16]. However,
these latter patients may differ from the general popula-
tion that GPs are managing, due to the extensively ap-
plied exclusion criteria for the older and sicker patients
[6]. Therefore, it remains unclear whether lowering SBP
in multimorbid and frail patients does in fact lead to
better outcomes. For example, in the SPRINT trial, frail
patients showed smaller intertreatment group differ-
ences in SBP compared to non-frail patients, thus a
lower SBP might be harder to achieve in frail patients
[16]. On the other hand, there is evidence that frail
oldest-old need a higher SBP. In a recent meta-analysis
comparing pro- and retrospective cohort studies, Zhang
et al. found that a higher SBP in frail oldest-old patients
had a protective effect in lowering the risk of overall
mortality [17]. Thus, current knowledge seems to be well
summarized by Materson et al. who suggested to evalu-
ate and treat frail oldest-old patients individually, while
the healthier oldest-old should be treated regardless of
their chronological age [18].
In the present study, this wide spectrum of recommen-
dations and lack of clear evidence may partly explain the
variation found between the participating countries. Dif-
ferences in national guidelines/campaigns may have also
led to differences between the countries. Nevertheless, this
study confirmed our hypothesis that frailty is a factor that
GPs take into consideration when starting antihyperten-
sive treatment; moreover, we found that GPs were less
likely to treat frail patients, even after adjusting for SBP
and CVD. This is in line with findings from a Dutch quali-
tative study, where vulnerability was an important patient-
related barrier for GPs when implementing guidelines for
secondary cardiovascular prevention in oldest-old [19].
Interestingly, our findings share some findings and yet
show difference with the only other published study on
this topic. Mermans et al. conducted a similar survey
among 305 GPs in Belgium. These authors also found
large differences in treatment intentions for hyperten-
sion in the oldest-old patients between GPs and showed
that there was a significant difference in the treatment
intention of GPs between robust patients and strongly
dependent patients. However, the stated that ‘differences
in the patients’ level of dependency were not responsible
for the variation in the overall treatment intention’ [20].
Table 2 Percentages of general practitioners (GPs) starting antihypertensive treatment for the eight individual cases (n = 2053 GPs)
Cases Proportion of GPs starting treatment Case Characteristics
% (95% CI) Frailty CVD SBP 160 mmHg
Overall 54.9 (54.1–55.7)
Case 1 17.3 (15.7–19.0) − − −
Case 2 18.2 (16.6–20.0) + − −
Case 3 85.4 (83.7–86.9) − − +
Case 4 75.6 (73.6–77.5) + − +
Case 5 96.8 (95.9–97.5) − + +
Case 6 84.9 (83.2–86.4) + + +
Case 7 32.5 (30.4–34.6) − + −
Case 8 29.5 (27.5–31.6) + + −
CVD cardiovascular disease, SBP systolic blood pressure
Although 2543 GPs participated, missing data on GPs’ decisions to treat the eight cases means that only 2053 GPs are included here
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However, on an international level, when including many
countries, frailty was established as an important factor
influencing GPs’ treatment decisions.
Strengths and limitations
A strength of this study is the high number of countries
and relatively large number of respondents (thanks to
collaboration with WONCA Europe, EGPRN, and
VdGM). Further, the sampled GPs were experienced with
treating oldest-old patients. The inclusion of many coun-
tries enabled to produce a detailed map of treatment
decision-making in Europe and elsewhere. In addition, we
could establish that, in most countries, frailty is associated
with a lower intention to treat, even when taking SBP and
cardiovascular comorbidity into account.
This study has several limitations. First, although we re-
port what the GPs stated they would do, this is not neces-
sarily the same as what they would actually do. However,
given the realistic case descriptions and the anonymous
nature of the survey, we are relatively confident that this
limitation has not introduced a systematic bias. Second,
the response rate varied considerably between countries
and the median rate was only 26%; this is a commonly oc-
curring problem in primary care surveys [21]. However,
our response rate was well within the range of other pub-
lished survey among GPs in major journals [22]. Several
reviews further noted that a low response rates in GP sur-
vey do not necessarily introduce selections bias [23, 24].
Third, in the case vignettes, only three patient characteris-
tics were taken into consideration. However, because we
focused on variation in treatment decision and the role of
frailty in that decision, it was beyond the scope of this
study to address all possible reasons related to GPs’ treat-
ment decision-making. Fourth, we mainly recruited one
GP network per country, which is a selection of GPs
dependent on their region of origin or area of interest;
however, by adjusting our analysis for GP characteristics
we aimed to take this possible confounder into account.
Implications
This study has several implications for research and clin-
ical practice. First, the large variation in starting treat-
ment in hypertensive oldest-old calls for high-quality
cohort studies or (ideally) new hypertension trials specif-
ically including frail patients to acquire evidence as to
whether frailty is indeed an important factor when treating
hypertension in oldest-old patients. Second, future studies
should investigate whether treatment variation might be ex-
plained by e.g. the recommendations in guidelines that indi-
vidual GPs follow. Third, qualitative studies could help us
to understand more of the variation we have found. If rea-
sons for the international variation in treatment are estab-
lished, educational campaigns can be launched to unify the
quality of care in Europe (and elsewhere) based on the
current body of evidence. Finally, future hypertension
guidelines should stratify their recommendations not only
for age, blood pressure level and cardiovascular comorbid-
ity, but also for frailty.
Conclusions
In Europe, Brazil, Israel and New Zealand, GPs’ deci-
sions concerning starting antihypertensive treatment in
the oldest-old varied considerably. Independently, the
frail oldest-old patients had an almost 50% lower prob-
ability for their GP to consider them eligible to receive
antihypertensive treatment. Future hypertension trials
should also include frail patients to acquire evidence on
the efficacy of antihypertensive treatment in oldest-old
patients with frailty, with the aim to support and unify
clinical decision-making.
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